
Please try another search
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, focused on acquiring, developing, and commercialising of medicines for unmet medical needs in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Ian O'Connell | 37 | 2021 | CFO & Director |
Jeremy Skillington | 53 | 2021 | CEO & Director |
Cathal Martin Friel | 60 | 2021 | Executive Chairman of The Board |
Elaine Sullivan | 63 | - | Member of Scientific Advisory Board |
Luke O’Neill | 60 | 2021 | Independent Non-Executive Director & Member of Scientific Advisory Board |
Edward Gibson | 51 | 2021 | Senior Independent Director |
Daniel F. Hoft | - | 2021 | Member of Scientific Advisory Board |
Brendan Mary Buckley | 74 | 2022 | Member of Scientific Advisory Board & Independent Non Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review